AstraZeneca PLC has said it should have Phase III data for its COVID-19 vaccine AZD1222 later in 2020 that might be sufficient for regulatory approval but stressed that the vaccine won't be a revenue driver if successful, as the group is focused on distributing it at a non-profit level.
The company updated markets on its COVID-19 response as it released another healthy set of quarterly financial results at this year’s half-way point that again highlighted its strong mid- and late-stage pipeline, which analysts said positions the British pharma for solid, deep-rooted long-term growth potential going forward